Table 1 Patient demographics.

Age, years

*0.0059^a

Mean (SD)

5 (5)

24 (23)

Median

5

15

Q1, Q3

1, 9

6, 44

Range

0–12

1–68

Sex

0.13^b

F

6 (75%)

12 (44%)

M

2 (25%)

15 (56%)

Tumor size, cm

0.093^a

Mean (SD)

6.6 (2.8)

4.6 (1.8)

Median

5.7

5

Q1, Q3

4.3, 8.5

3.6, 5.4

Range

3.8–11.2

1.0–8.7

Location

*0.019^b

Cerebral hemisphere

3 (37.5%)

20 (74%)

Posterior fossa

4 (50%)

2 (7%)

Thalamus, ventricle & spinal cord

1 (12.5%)

5 (19%)

Histological grading

0.33^b

WHO Grade III

1 (12.5%)

8 (30%)

WHO Grade IV

7 (87.5%)

19 (70%)

Tumor classification

0.20^b

Diffuse astrocytic and oligodendroglial^c

3 (37.5%)

15 (56%)

Embryonal^d

4 (50%)

5 (19%)

Ependymal, neuronal and others^e

1 (12.5%)

7 (26%)

Tumor medical history

0.68^b

De novo

6 (75%)

22 (81%)

Recurrent

2 (25%)

5 (19%)

Ki-67 proliferation index, %

0.71^a

Mean (SD)

22 (21)

22 (16)

Median

15

18

Q1, Q3

5, 38

11, 33

Range

1–54

2–59

Molecular features

IDH mutation

1 (100%)

1 (6%)

*0.0048^b

IDH wildtype

0

15 (94%)

IDH unknown

7

11

TB53 mutation

3 (50%)

9 (50%)

1.00^b

TP53 wildtype

3 (50%)

9 (50%)

TP53 unknown

2

9

EGFR amplification

0

3 (21%)

0.26^b

EGFR unamplied

5 (100%)

11 (79%)

EGFR unknown

3

13